Introduction: Adjuvant or salvage systemic therapy after nephrectomy for intermediate- and high-risk clear cell renal cell carcinoma (ccRCC) improves overall survival. However, severe renal impairment represents a relative contraindication to systemic therapy administration. This study aimed to analyze the impact of overweight and obesity at the time of nephrectomy in determining subsequent renal function impairment and limited accessibility to systemic therapy. Methods: Within a prospectively maintained database, we identified 795 nonmetastatic ccRCC patients at intermediate or high risk of recurrence. BMI was calculated as weight/height (kg/m2), and chronic kidney disease (CKD) upstage was defined as estimated glomerular filtration rate <30 mL/min/1.73 m2. Multivariable Cox regression models assessed the association between BMI and the risk of CKD upstage. Cumulative incidence curves illustrated the risk of disease relapse across different risk groups. Results: Overall, 504 (63%) were classified as intermediate and 291 (37%) as high risk of recurrence. The median BMI was 26 kg/m2 (IQR: 24–28), with 407 (51%) patients being overweight and 89 (11%) classified as obese. The 5-year risk of disease recurrence was 20% for intermediate and 70% for high-risk patients (p < 0.001). After accounting for patient, surgical, and tumor characteristics, the adjusted risk of CKD upstage increased from 24%–35% to 42%–61% in normal vs. overweight vs. obese patients. BMI resulted as an independent predictor of CKD upstage (hazard ratio [HR] 1.08, p = 0.04). Specifically, overweight (HR: 2.11) and obese (HR: 3.26) patients were at higher risk of CKD upstage (all p < 0.05). Conclusion: BMI emerges as an important marker of vulnerability to clinically meaningful postoperative renal function decline. Patients with intermediate- or high-risk ccRCC who are overweight or obese may benefit from structured multidisciplinary evaluation, including nutritional assessment, to preserve renal reserve and maintain eligibility for adjuvant or salvage systematic treatments when indicated.

1.
National Institute of Diabetes and Digestive and Kidney Diseases. Overweight and Obesity Statistics
. 2021. [Internet]. [cited 2025 Jan 25]. Available from: https://www.niddk.nih.gov/
2.
Rigby
N
.
Eating and obesity: the new world disorder
.
Nutrients
.
2013
;
5
(
10
):
4206
10
.
3.
World Health Organization
.
Obesity and overweight
.
World Health Organization
;
2024
. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
4.
Liu
X
,
Sun
Q
,
Hou
H
,
Zhu
K
,
Wang
Q
,
Liu
H
, et al
.
The association between BMI and kidney cancer risk: an updated dose-response meta-analysis in accordance with PRISMA guideline
.
Medicine
.
2018
;
97
(
44
):
e12860
.
5.
Renehan
AG
,
Tyson
M
,
Egger
M
,
Heller
RF
,
Zwahlen
M
.
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies
.
Lancet
.
2008
;
371
(
9612
):
569
78
.
6.
Ormazabal
V
,
Nair
S
,
Elfeky
O
,
Aguayo
C
,
Salomon
C
,
Zuñiga
FA
.
Association between insulin resistance and the development of cardiovascular disease
.
Cardiovasc Diabetol
.
2018
;
17
(
1
):
122
.
7.
Kovesdy
CP
,
Furth
SL
,
Zoccali
C
;
World Kidney Day Steering Committee
.
Obesity and kidney disease: hidden consequences of the epidemic
.
Can J Kidney Health Dis
.
2017
;
4
:
2054358117698669
.
8.
Herrington
WG
,
Smith
M
,
Bankhead
C
,
Matsushita
K
,
Stevens
S
,
Holt
T
, et al
.
Body-mass index and risk of advanced chronic kidney disease: prospective analyses from a primary care cohort of 1.4 million adults in England
.
PLoS One
.
2017
;
12
(
3
):
e0173515
.
9.
Scilipoti
P
,
Rosiello
G
,
Belladelli
F
,
Pellegrino
F
,
Trevisani
F
,
Bettiga
A
, et al
.
Exploring the effect of patient characteristics on the association between warm ischemia time and the risk of postoperative acute kidney injury after partial nephrectomy
.
Urol Oncol
.
2025
;
43
(
5
):
333.e1
8
.
10.
Scilipoti
P
,
Rosiello
G
,
Belladelli
F
,
Gambirasio
M
,
Trevisani
F
,
Bettiga
A
, et al
.
The detrimental effect of metabolic syndrome on long-term renal function in patients undergoing elective partial nephrectomy for small renal masses
.
Eur Urol Open Sci
.
2024
;
69
:
73
9
.
11.
Schmid
M
,
Abd-El-Barr
AE
,
Gandaglia
G
,
Sood
A
,
Olugbade
K
Jr
,
Ruhotina
N
, et al
.
Predictors of 30-day acute kidney injury following radical and partial nephrectomy for renal cell carcinoma
.
Urol Oncol
.
2014
;
32
(
8
):
1259
66
.
12.
Rosiello
G
,
Larcher
A
,
Fallara
G
,
Giancristofaro
C
,
Martini
A
,
Re
C
, et al
.
Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma
.
Urol Oncol
.
2022
;
40
(
6
):
271.e19
27
.
13.
Motzer
RJ
,
Bex
A
,
Russo
P
,
Tomita
Y
,
Cutuli
HJ
,
Rojas
C
, et al
.
Adjuvant nivolumab for localized renal cell carcinoma at high risk of recurrence after nephrectomy: part B of the randomized, placebo-controlled, phase III CheckMate 914 trial
.
J Clin Oncol
.
2025
;
43
(
2
):
189
200
.
14.
Choueiri
TK
,
Tomczak
P
,
Park
SH
,
Venugopal
B
,
Ferguson
T
,
Symeonides
SN
, et al
.
Overall survival with adjuvant pembrolizumab in renal-cell carcinoma
.
N Engl J Med
.
2024
;
390
(
15
):
1359
71
.
15.
Ljungberg
B
,
Albiges
L
,
Abu-Ghanem
Y
,
Bedke
J
,
Capitanio
U
,
Dabestani
S
, et al
.
European Association of Urology Guidelines on renal cell carcinoma: the 2022 update
.
Eur Urol
.
2022
;
82
(
4
):
399
410
.
16.
European Medicines Agency
.
Authorisation of medicines: European Medicines Agency
.
European Medicines Agency
. Published September 17, 2018. Available from: https://www.ema.europa.eu/en/about-us/what-we-do/authorisation-medicines
17.
Levey
AS
,
Stevens
LA
,
Schmid
CH
,
Zhang
YL
,
Castro
AF
3rd
,
Feldman
HI
, et al
.
A new equation to estimate glomerular filtration rate
.
Ann Intern Med
.
2009
;
150
(
9
):
604
12
.
18.
Vickers
AJ
,
Sjoberg
DD
;
European Urology
.
Guidelines for reporting of statistics in European Urology
.
Eur Urol
.
2015
;
67
(
2
):
181
7
.
19.
Thomas
G
,
Sehgal
AR
,
Kashyap
SR
,
Srinivas
TR
,
Kirwan
JP
,
Navaneethan
SD
.
Metabolic syndrome and kidney disease: a systematic review and meta-analysis
.
Clin J Am Soc Nephrol
.
2011
;
6
(
10
):
2364
73
.
20.
Obermayr
RP
,
Temml
C
,
Knechtelsdorfer
M
,
Gutjahr
G
,
Kletzmayr
J
,
Heiss
S
, et al
.
Predictors of new-onset decline in kidney function in a general Middle-European population
.
Nephrol Dial Transplant
.
2008
;
23
(
4
):
1265
73
.
21.
Navarro Díaz
M
.
Consequences of morbid obesity on the kidney. Where are we going
.
Clin Kidney J
.
2016
;
9
(
6
):
782
7
.
22.
Richards
KA
,
Negron
E
,
Cohn
JA
,
Steinberg
Z
,
Eggener
SE
,
Shalhav
AL
.
The impact of body mass index on renal functional outcomes following minimally invasive partial nephrectomy
.
J Endourol
.
2014
;
28
(
11
):
1338
44
.
23.
Calder
CL
,
Ortega
G
,
Vij
A
,
Chawla
K
,
Nnamdi-Emetarom
C
,
Stephanie
S
, et al
.
Morbid obesity is an independent risk factor for postoperative renal dysfunction in young adults: a review of the American College of Surgeons National Surgical Quality Improvement Program database
.
Am J Surg
.
2016
;
211
(
4
):
772
7
.
24.
van der Mijn
JC
,
Al Hussein Al Awamlh
B
,
Islam Khan
A
,
Posada-Calderon
L
,
Oromendia
C
,
Fainberg
J
, et al
.
Validation of risk factors for recurrence of renal cell carcinoma: results from a large single-institution series
.
PLoS One
.
2019
;
14
(
12
):
e0226285
.
25.
Hu
SL
,
Weiss
RH
.
The role of nephrologists in the management of small renal masses
.
Nat Rev Nephrol
.
2018
;
14
(
4
):
211
2
.
26.
Ganesan
C
,
Pao
AC
,
Leppert
JT
.
The nephrologist’s role in the management of kidney cancer: a Renaissance
.
Am J Kidney Dis
.
2023
;
82
(
6
):
644
6
.
27.
Trevisani
F
,
Paccagnella
M
,
Angioi
A
,
Fiorio
F
,
Floris
M
,
Pontara
A
, et al
.
The role of maintaining nutritional adequacy status and physical activity in onco-nephrology: not a myth anymore, but a reality
.
Nutrients
.
2025
;
17
(
2
):
335
.
28.
Tirosh
A
,
Golan
R
,
Harman-Boehm
I
,
Henkin
Y
,
Schwarzfuchs
D
,
Rudich
A
, et al
.
Renal function following three distinct weight loss dietary strategies during 2 years of a randomized controlled trial
.
Diabetes Care
.
2013
;
36
(
8
):
2225
32
.
29.
Scilipoti
P
,
Moschini
M
,
Li
R
,
Lerner
SP
,
Black
PC
,
Necchi
A
, et al
.
The financial burden of localized and metastatic bladder cancer
.
Eur Urol
.
2025
;
87
(
5
):
536
50
.
30.
Blonde
L
,
Khunti
K
,
Harris
SB
,
Meizinger
C
,
Skolnik
NS
.
Interpretation and impact of real-world clinical data for the practicing clinician
.
Adv Ther
.
2018
;
35
(
11
):
1763
74
.
31.
Motzer
RJ
,
Rini
BI
,
McDermott
DF
,
Arén Frontera
O
,
Hammers
HJ
,
Carducci
MA
, et al
.
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
.
Lancet Oncol
.
2019
;
20
(
10
):
1370
85
.
32.
Rini
BI
,
Plimack
ER
,
Stus
V
,
Gafanov
R
,
Hawkins
R
,
Nosov
D
, et al
.
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
.
N Engl J Med
.
2019
;
380
(
12
):
1116
27
.
33.
Motzer
R
,
Alekseev
B
,
Rha
SY
,
Porta
C
,
Eto
M
,
Powles
T
, et al
.
Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma
.
N Engl J Med
.
2021
;
384
(
14
):
1289
300
.
You do not currently have access to this content.